FUZE Clinical Trial: a Phase 2 study of Debio 1347 in FGFR fusion-positive advanced solid tumors irrespectively of the tumor histology

Presented at ASCO 2019, Chicago, Il, US

David Michael Hyman1, Lipika Goyal2, Petros Grivas3, Funda Meric-Bernstam4, Josep Tabernero5, Youyou Hu6, Yulia Kirpicheva6, Valerie Nicolas-Metral6, Anna Pokorska-Bocci6, Anne Vaslin6, Claudio Zanna6, Keith Flaherty2, 7

  1. Memorial Sloan Kettering Cancer Center, New York, NY;
  2. Massachusetts General Hospital, Boston, MA;
  3. University of Washington, School of Medicine, Seattle, WA;
  4. The University of Texas MD Anderson Cancer Center, Houston, TX;
  5. Vall d’Hebron University Hospital and Institute of Oncology, University Autònoma de Barcelona, Barcelona, Spain;
  6. Debiopharm International SA, Lausanne, Switzerland;
  7. Dana-Farber Cancer Institute/Harvard Medical School